Moderna, Novavax Developing Combined Single-Dose COVID-19 and Influenza Vaccine
American pharmaceutical and biotechnology company Moderna, Inc., which partnered with the U.S. National Institutes of Allergy and Infectious Diseases (NIAID) to develop an mRNA COVID-19 vaccine being distributed in the United States under an Emergency Use Authorization (EUA) announced that it is developing a combined single-dose booster vaccine for COVID-19 and seasonal influenza.1 In a […]
Novavax’s Adjuvanted COVID-19 Vaccine Caused Severe Adverse Reactions in Clinical Trials
Biotechnology company Novavax, Inc. of Gaithersburg, Maryland recently made public the results of the Phase 1 part of a Phase 1/2 human clinical trial for its experimental NVX-CoV2373 vaccine for COVID-19. According to Novavax, “NVX‑CoV2373 was created using Novavax’s recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’s […]
